Rovafovir etalafenamide - Gilead Sciences
Alternative Names: GS 9148 phosphonoamidate prodrug; GS-9131Latest Information Update: 26 Apr 2022
At a glance
- Originator Gilead Sciences
- Class Amines; Antiretrovirals; Furans; Phosphoric Acids; Propionates; Purine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended HIV-1 infections
Most Recent Events
- 26 Apr 2022 No development reported - Phase-II for HIV-1 infections (Treatment-experienced) in Zimbabwe, Uganda (PO)
- 28 Apr 2020 Gilead Sciences terminates a phase II trial in HIV-1 infections (Treatment-experienced) in Zimbabwe and Uganda and Zimbabwe due to failure of meeting targeted antiviral response (PO, Tablet) (NCT03472326)
- 03 Apr 2018 Phase-II clinical trials in HIV-1 infections (Treatment-experienced) in Uganda (PO, Tablet) (NCT03472326)